Factor XIII-A subunit Val34Leu polymorphism is associated with the risk of thrombosis in patients with antiphospholipid antibodies and high fibrinogen levels

Gloria de la Red; Dolores Tàssies; Gerard Espinosa; Joan Monteagudo; Albert Bové; Joan Plaza; Ricard Cervera; Joan-Carles Reverter

doi:10.1160/TH08-06-0347

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2009; 101(02): 312-316
DOI: 10.1160/TH08-06-0347

Blood Coagulation, Fibrinolysis and Cellular Haemostasis

Schattauer GmbH

Factor XIII-A subunit Val34Leu polymorphism is associated with the risk of thrombosis in patients with antiphospholipid antibodies and high fibrinogen levels^[*]

Gloria de la Red

¹Department of Autoimmune Diseases, Institut Clínic de Medicina i Dermatologia, Barcelona, Catalonia, Spain

,

Dolores Tàssies

²Department of Hemotherapy and Hemostasis, Hospital Clinic, Barcelona, Catalonia, Spain

,

Gerard Espinosa

¹Department of Autoimmune Diseases, Institut Clínic de Medicina i Dermatologia, Barcelona, Catalonia, Spain

,

Joan Monteagudo

²Department of Hemotherapy and Hemostasis, Hospital Clinic, Barcelona, Catalonia, Spain

,

Albert Bové

¹Department of Autoimmune Diseases, Institut Clínic de Medicina i Dermatologia, Barcelona, Catalonia, Spain

,

Joan Plaza

¹Department of Autoimmune Diseases, Institut Clínic de Medicina i Dermatologia, Barcelona, Catalonia, Spain

,

Ricard Cervera

¹Department of Autoimmune Diseases, Institut Clínic de Medicina i Dermatologia, Barcelona, Catalonia, Spain

,

Joan-Carles Reverter

²Department of Hemotherapy and Hemostasis, Hospital Clinic, Barcelona, Catalonia, Spain

› Author Affiliations

Abstract

Summary

Recent reports have described the factor XIII A subunit (FXIII-A) Val34Leu polymorphism as a protective factor against venous and arterial thrombosis. The aim of this study was to investigate the association between the FXIII-A Val34Leu polymorphism, its interaction with fibrinogen concentration, and thrombosis in patients with antiphospholipid antibodies (aPL). We included 172 consecutive patients with aPL: 88 with primary antiphospholipid syndrome (APS), 38 with APS associated with systemic lupus erythematosus (APS-SLE), 32 with SLE and aPL but without APS (SLE-aPL), and 14 asymptomatic individuals with aPL (A-aPL). The FXIII-A Val34Leu polymorphism was assessed by polymerase chain reaction techniques. We found no significant differences in FXIII-A Leu34 allele frequencies between primary APS (allele frequency 0.22), APS-SLE (0.23), SLE-aPL (0.22) and A-aPL (0.32) patients, or between patients with (0.21) and without thrombosis (0.26). FXIII-A Leu34 allele frequencies were significantly lower in patients with thrombosis and those in the upper fibrinogen tertile (>3.40 g/l) (allele frequency 0.07) compared with patients without thrombosis in the upper fibrinogen tertile (0.29) and patients with (0.29) and without (0.25) thrombosis in the mid- and lower fibrinogen tertiles. The FXIII-A Leu34 allele had a protective effect against thrombosis in patients in the upper fibrinogen tertile (odds ratio [OR]=0.20, 95% confidence interval [CI] 0.07–0.60) but not in those in the other tertiles (OR=1.20, 95% CI 0.67–2.16). The FXIII-A Leu34 allele seems to have a protective effect on the development of thrombosis in patients with aPL, but only in those with high plasma fibrinogen values.

Keywords

Factor XIII polymorphism - antiphospholipid antibodies - fibrinogen - thrombosis

Full Text

References

References
1 Ichinose A. The physiology and biochemistry of factor XIII. In: Haemostasis and Thrombosis. 3^rd ed. Churchill Livingstone; 1994: 531-546.
2 Schwartz ML, Pizzo SV, Hill RL. et al. Human factor XIII from plasma and platelets: molecular weights, subunit structures, proteolytic activation, and cross-linking of fibrinogen and fibrin. J Biol Chem 1973; 248: 1395-1407.
3 Mikkola H, Syrjälä M, Rasi V. et al. Deficiency in the A-subunit of coagulation factor XIII: two novel point mutations demonstrate different effects on transcript levels. Blood 1994; 84: 517-525.
4 Kohler HP, Stickland HM, Ossei-Gerning N. et al. Association of a common polymorphism in the factor XIII gene with myocardial infarction. Thromb Haemost 1998; 79: 8-13.
5 Shafey M, Anderson JL, Scarvelis D. et al. Factor XIII Val34Leu variant and the risk of myocardial infarction: a meta-analysis. Thromb Haemost 2007; 97: 635-641.
6 Vokó Z, Bereczky Z, Katona E. et al. Factor XIII Val34Leu variant protects against coronary artery disease. A meta-analysis. Thromb Haemost 2007; 97: 458-463.
7 Rallidis LS, Politou M, Komporozos C. et al. Factor XIII Val34Leu polymorphism and the risk of myocardial infarction under the age of 36 years. Thromb Haemost 2008; 99: 1085-1089.
8 Elbaz A, Poirier O, Canaple S. et al. The association between the Val34Leu polymorphism in the factor XIII gene and brain infarction. Blood 2000; 95: 586-591.
9 Slowik A, Dziedzic T, Pera J. et al. Coagulation factor XIII in patients with small vessel disease or primary intracerebral hemorrhage. Cerebrovasc Dis 2005; 19: 165-170.
10 Catto AJ, Kohler HP, Mansfield MW. et al. Association of a common polymorphism in the factor XIII gene with venous thrombosis. Blood 1999; 93: 906-908.
11 Franco RF, Reistma PH, Lourenco D. et al. Factor XIII Val34Leu is a genetic factor involved in the etiology of venous thrombosis. Thromb Haemost 1999; 81: 676-679.
12 Renner W, Koppel H, Hoffmann C. et al. Prothrombin G20210A, factor V Leiden, and factor XIII Val 34Leu: common mutations of blood coagulation factors and deep vein thrombosis in Austria. Thromb Res 2000; 99: 35-39.
13 Zidane M, de Visser MC, ten Wolde M. et al. Frequency of the TAFI-438 G/A and factor XIIIA Val34Leu polymorphisms in patients with objectively proven pulmonary embolism. Thromb Haemost 2003; 90: 439-445.
14 Van Hylckama Vlieg A, Komanasin N, Ariens RA. et al. Factor XIII Val34Leu polymorphism, factor XIII antigen levels and activity and the risk of deep venous thrombosis. Br J Haematol 2002; 119: 169-175.
15 Ariens RAS, Philippou H, Nagaswami C. et al. The factor XIIIV34L polymorphism accelerates thrombin activation of factor XIII and affects cross-linked fibrin structure. Blood 2000; 96: 988-995.
16 Corral J, Gonzalez-Conejero R, Iniesta JA. et al. The FXIII Val34Leu polymorphism in venous and arterial thromboembolism. Haematologica 2000; 85: 293-297.
17 Roldan V, Corral J, Marin F. et al. Role of factor XIII Val34Leu polymorphism in patients <45 years of age with acute myocardial infarction. Am J Cardiol 2003; 91: 1242-1245.
18 Atherosclerosis, Thrombosis, and Vascular Biology Italian Study Group.. No evidence of association between prothombotic gene polymorphisms and the development of acute myocardial infarction at a young age. Circulation 2003; 107: 1117-1122.
19 Lim BCB, Ariens RA, Carter AM. et al. Genetic regulation of fibrin structure and function: complex gene-environment interactions may modulate vascular risk. Lancet 2003; 361: 1424-1431.
20 Salmon J, de Groot D. Pathogenic role of antiphospholipid antibodies. Lupus 2008; 17: 405-411.
21 Diz-Kucukkaya R, Hancer VS, Inanc M. et al. Factor XIII Val34Leu polymorphism does not contribute to the prevention of thrombotic complications in patients with antiphospholipid syndrome. Lupus 2004; 13: 32-35.
22 Brandt JT, Triplett DA, Alving B. et al. Criteria for the diagnosis of lupus anticoagulant: an update. Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the ISTH. Thromb Haemost 1995; 74: 1185-1190.
23 Miyakis S, Lockshin MD, Atsumi T. et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4: 295-306.
24 Tan EM, Cohen AS, Fries JF. et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271-1277.
25 Henry M, Morange PE, Canavy I. et al. Rapid detection of factor XIII Val34Leu by allele specific PCR. Thromb Haemost 1999; 81: 463.
26 Zapata C, Alvarez G. On Fisher´s exact test for detecting gametic disequilibrium between DNA polymorphisms. Ann Hum Genet 1997; 61: 71-77.
27 Kahn HA. Relative risk and odds ratio. In: An introduction to epidemiologic methods. Oxford University Press; 1983: 38-55.
28 Hornyak TJ, Shafer JA. Role of calcium ion in the generation of factor XIII activity. Biochemistry 1991; 30: 6175-6182.
29 Ames PR, Iannaccone L, Alves JD. et al. Factor XIII in primary antiphospholipid syndrome. J Rheumatol 2005; 32: 1058-1062.
30 Wilmer M, Rudin K, Kolde HJ. et al. Evaluation of a sensitive colorimetric FXIII incorporation assay. Effects of FXIII Val34Leu, plasma fibrinogen concentration and congenital FXIII deficiency. Thromb Res 2001; 102: 81-91.
31 Kobbervig C, Williams E. FXIII polymorphisms, fibrin clot structure and thrombotic risk. Biophys Chem 2004; 112: 223-228.
32 Scott EM, Ariens RA, Grant PJ. Genetic and environmental determinants of fibrin structure and function: relevance to clinical disease. Arterioscler Thromb Vasc Biol 2004; 24: 1558-1566.
33 Vossen CY, Rosendaal FR. The protective effect of the factor XIII Val34Leu mutation on the risk of deep venous thrombosis is dependent on the fibrinogen level. J Thromb Haemost 2005; 3: 1102-1103.
34 Boekholdt SM, Sandhu MS, Wareham NJ. et al. Fibrinogen plasma levels modify the association between the factor XIII Val34Leu variant and risk of coronary artery disease: the EPIC-Norfolk prospective population study. J Thromb Haemost 2006; 4: 2204-2209.
35 Bereczky Z, Balogh E, Katona E. et al. Modulation of the risk of coronary sclerosis/myocardial infarction by the interaction between factor XIII subunit A Val34Leu polymorphism and fibrinogen concentration in the high risk Hungarian population. Thromb Res 2007; 120: 567-573.

Factor XIII-A subunit Val34Leu polymorphism is associated with the risk of thrombosis in patients with antiphospholipid antibodies and high fibrinogen levels[*]

Factor XIII-A subunit Val34Leu polymorphism is associated with the risk of thrombosis in patients with antiphospholipid antibodies and high fibrinogen levels^[*]